{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:12:46Z","timestamp":1771834366226,"version":"3.50.1"},"reference-count":5,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0252","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:22:58Z","timestamp":1756290178000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Response to Single-Agent Lenalidomide in an Elderly Patient with Relapsed Hepatosplenic T-Cell Lymphoma"],"prefix":"10.4274","author":[{"given":"S\u00fcreyya","family":"Yi\u011fit Kaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima","family":"Akil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcl\u015fah","family":"Akyol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Hossein","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhat","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leylag\u00fcl","family":"Kaynar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"513702","DOI":"10.1155\/2012\/513702","article-title":"Molecular action of lenalidomide in lymphocytes and hematologic malignancies","volume":"2012","author":"McDaniel","year":"2012","unstructured":"1. McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol. 2012;2012:513702.","journal-title":"Adv Hematol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"882","DOI":"10.5306\/wjco.v12.i10.882","article-title":"Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas","volume":"12","author":"Cencini","year":"2021","unstructured":"2. Cencini E, Fabbri A, Mecacci B, Bocchia M. Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas. World J Clin Oncol. 2021;12:882-896.","journal-title":"World J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","unstructured":"3. Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, van der Jagt R, Stewart D, White D, Belch A, Reiman T. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121:716-723.","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Kim SJ, Lee MW, Lim SN, Kang KW, Yoon SE, Lee YJ, Kang HJ, Lee HS, Kim HJ, Koo HH, Shin HJ, Eom HS, Won JH, Kim WS. Phase II study of lenalidomide maintenance after salvage therapy for relapsed or refractory peripheral T-cell lymphomas. Blood. 2023;142(Suppl 1):3073.","DOI":"10.1182\/blood-2023-181809"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","unstructured":"5. Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49:2869-2876.","journal-title":"Eur J Cancer"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T07:37:28Z","timestamp":1771832248000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-32748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":5,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0252","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}